A study testing whether a GLP-1 medicine, semaglutide, may help during breast cancer treatment.

Who can join: Adults 46 to 55, women only, have breast cancer, BMI 30+.
What you take: Semaglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 9 years.
What you get: Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 4Sponsor Mayo ClinicDrug semaglutideClass GLP-1 RASites 1 USEnrollment target 50

What this study is for

Primary condition: Anatomic Stage I Breast Cancer AJCC v8. Also studied in: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8.

Full scientific study title: Semaglutide and Structured Lifestyle Support to Improve Heart and Blood Vessel Health in Postmenopausal Obese Breast Cancer Survivors Taking.

Who can join

Age46 to 55SexFemaleBMI30 or higher

Adults 46 to 55, women only, have breast cancer, BMI 30+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Breast cancer diagnosed after menopause (menopause defined as the natural/spontaneous cessation of menses for at least 12 months)
Breast cancer (BC) diagnosed within the past five years
BC stage 1, 2, or 3
Aged 46-55 years
Body mass index (BMI) ≥ 30 kg/m\^²

Key exclusion criteria

\> 5% change in weight during the 3 months prior to screening and/or weight fluctuation of ≥ 20 pounds within the past 6 months (self-report)
Early menopause (menopause occurring before age 46)
History of established cardiovascular disease, including coronary atherosclerosis, ischemic heart disease, peripheral vascular disease, or stroke
Statin use
10-year Atherosclerotic Cardiovascular Disease (ASCVD) risk \> 7.5%

Where this trial runs

This trial has 1 sites across 1 state. Site contacts are listed for reference. They are not screening through this trial right now.

Florida1 site

Mayo Clinic in Florida
Jacksonville, Florida
General Clinical Studies Unit904-953-2255

Follow this trial

We email you if NCT07769047 changes status, adds new sites in your state, or if a similar trial opens for the same condition.

Timeline

Scheduled start: September 1, 2026. Expected completion: July 30, 2035. Last updated on ClinicalTrials.gov: August 17, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site LinkedIn Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.